Ardelyx, Inc.
NASDAQ:ARDXBiotechnology
-$0.06 today
- Market cap
- $784.28M
- Beta
- 0.58
- P/E (TTM)
- -24.5
- EPS (TTM)
- -$0.24
Volume 4.75M
Average 3.58M
ARDX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Ardelyx, Inc.NASDAQ: ARDX
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows in line with its trailing trend
Q1 FY2026 depreciation & amortization of $915K rose 52.0% year over year, ahead of the +51.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 0.7% from the prior quarter. Over 3 fiscal years it compounded at +38.8% a year.
Context
- Depreciation & amortization amounted to 0.8% of revenue in FY2025, up 0.1 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +52.0% holds above the trailing-twelve-month pace of +51.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 3.06M USD
- Year-over-year change
- +48.3%
- 4-year CAGR
- +20.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.06M | +48.3% |
| FY2024 | 2024-12-31 | 2.06M | +59.7% |
| FY2023 | 2023-12-31 | 1.29M | +12.9% |
| FY2022 | 2022-12-31 | 1.14M | -20.6% |
| FY2021 | 2021-12-31 | 1.44M | — |
Depreciation & Amortization vs competitors
How ARDX compares with its peers on the latest reported figures
- ARDX's LTM Mar 2026 depreciation & amortization of $3.37M is the 2nd largest of the 5 companies compared; the peer median is $1.72M.
- Its year-over-year change of +51.2% is the highest of 5, against a peer median of -12.8%.
- Depreciation & amortization amounts to 0.8% of revenue for ARDX, versus a peer median of 4.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $12.47M | +3.0% | -1.4% | 4.0% | |
| LTM Mar 2026 | $3.37M | +51.2% | +38.8% | 0.8% | |
| LTM Mar 2026 | $2.16M | -28.6% | -14.3% | 10.8% | |
| LTM Mar 2026 | $1.28M | -96.1% | -67.7% | 0.6% | |
| LTM Mar 2026 | $52K | +23.8% | — | — | |
| Peer median (excluding ARDX) | $1.72M | -12.8% | -14.3% | 4.0% | |
Competitors are the stored peer set for ARDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (158.17M) | (67.21M) | (66.07M) | (39.14M) | (61.6M) |
| Depreciation & Amortization | 1.44M | 1.14M | 1.29M | 2.06M | 3.06M |
| Deferred Income Tax | (190K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 12.04M | 10.75M | 13.53M | 37.38M | 48.96M |
| Change in Working Capital | (11.92M) | (19.58M) | (43.39M) | (49.17M) | (31.35M) |
| Accounts Receivables | (502K) | (7.23M) | (14.3M) | (35.67M) | (14.14M) |
| Inventory | (10.37M) | (28.35M) | (21.14M) | (41.7M) | (31.92M) |
| Accounts Payables | (1.35M) | 6.58M | 279K | 4.86M | 3.24M |
| Other Working Capital | 300K | 9.42M | (8.23M) | 23.34M | 11.48M |
| Other Non-Cash Items | 4.25M | 4.84M | 4.91M | 4.05M | (1.55M) |
| Operating Cash Flow | (152.55M) | (70.04M) | (89.72M) | (44.81M) | (42.48M) |
| Capital Expenditures | (1.87M) | (55K) | (344K) | (1.01M) | (1.49M) |
| Acquisitions (Net) | (52.82M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (72.74M) | (50.33M) | (215.23M) | (195.16M) | (218.92M) |
| Sales of Investments | 125.55M | 67M | 84.32M | 177.85M | 211.46M |
| Other Investing Activities | 52.82M | 1.8M | 0 | 0 | 0 |
| Investing Cash Flow | 50.95M | 18.42M | (131.25M) | (18.32M) | (8.96M) |
| Debt Repayment | (19.44M) | (6.07M) | 22.39M | 99.45M | 48.67M |
| Common Stock Issued | 101.15M | 71.63M | 119.24M | 8.14M | 5.84M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.3M | 9.78M | 4.67M | (1M) | 0 |
| Financing Cash Flow | 83M | 75.34M | 146.3M | 106.59M | 54.51M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (18.6M) | 23.71M | (74.67M) | 43.46M | 3.07M |
| Free Cash Flow | (154.42M) | (70.1M) | (90.06M) | (45.82M) | (43.98M) |
Ardelyx, Inc.
NASDAQ:ARDX
Intrinsic Alpha fair value
Locked
Current Price
$3.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.